

FGFR2 FISH TESTING IN CHOLANGIOCARCINOMA

Background

Cholangiocarcinoma is a rare cancer that develops from the epithelial lining of the bile ducts. It is classified as intrahepatic or extrahepatic, based on the location of the primary tumour. Cholangiocarcinoma is an aggressive disease with a poor prognosis. 70% of patients are diagnosed late with unresectable, locally advanced or metastatic disease.

Fibroblast growth factor receptor 2 (**FGFR2**) gene fusion or rearrangement are present in approximately 10% of cholangiocarcinoma and may lead to tumour formation.

NICE have recently recommended the use of Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with a FGFR2 gene fusion or rearrangement. <https://www.nice.org.uk/guidance/ta722>

The AWMGS will use fluorescence in situ hybridization (FISH) to test for FGFR2 gene fusion and rearrangements.

Test (Price available on request)	TAT(calendar days)
FISH test for FGFR2 rearrangements	14

Sample Requirements

- 1 H&E stained slide with area of highest neoplastic cell content CLEARLY circled
- 3 x 3-4µM sections (singly mounted) on charged/adhesion slides

All samples must be accompanied by [request form](#)

Consent for testing is assumed when request for test received

Contact Details

All Wales Genomics Laboratory,
Institute of Medical Genetics,
University Hospital of Wales,
Heath Park,
Cardiff CF14 4XW
Tel: 029 2074 2641
Fax: 029 2074 4043

lab.genetics@wales.nhs.uk
<https://www.medicalgenomicswales.co.uk/>

Accredited to ISO 15189:2012
(8988)